logo

Michael Gahnyam Gbeungvat Foundation, Inc.

Buea, Cameroon
Joined December 2024

Michael GG Foundation is a nonprofit working to meet the health needs of persons with disabilities. Activities include; research, outreach campaigns, health & social interventions, and policy advocacy



Presence in: Cameroon, United States
Focus: Disability Rights, Health, Policy Advocacy

Michael Gahnyam Gbeungvat Foundation (Michael GG Foundation) is a nonprofit, nonracial, and nondenominational organization based in Buea, Cameroon, and Atlanta, USA. The overall objective of Michael GG Foundation is to meet the health aspirations of persons with disabilities and the less privileged. The activities of Michael GG Foundation include; carrying out health interventions to increase access to health services in remote communities and improving the life quality of persons with disabilities (https://www.facebook.com/MGGFoundation/), researching factors that affect COVID-19 vaccine acceptance amongst Cameroonians (Dinga et al., 2021, 2022a) and in 185 countries (Dinga et al., 2024a), and advocacy to enact evidence-based policies to prepare for future pandemics (Dinga et al., 2022b, Titanji et al., 2022). Michael GG Foundation also contributed to a study on malaria vaccine acceptance in Cameroon (Njoh et al., 2024) and did a meta-analysis to assess the association between gross domestic product with access to childhood vaccines in 195 countries (Dinga et al., 2024b). Other activities include attending international conferences and a series of other oral presentations. ……………………………….We would like to join forces with like-minded people, and partners in the business world, legal, media, and social, so that together, we will create an inclusive, equitable, accessible world for persons with disabilities in Cameroon and the world at large. …………….

References:

(1) DOI:10.3390/vaccines9020175 (Dinga et al., 2021),

(2) DOI:10.3390/vaccines10091401 (Dinga et al., 2022a),

(3) DOI:10.4314/jcas.v18supplement.7 (Dinga et al., 2022b),

(4) DOI:10.13140/RG.2.2.16029.59365 (Titanji et al., 2022),

(5) DOI:10.3390/vaccines12010034 (Dinga et al., 2024a),

(6) DOI:10.2139/ssrn.4814538 (Dinga et al., 2024b),

(7) DOI:10.2139/ssrn.4712743 (Njoh et al., 2024).